These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. Ferrantini C; Pioner JM; Mazzoni L; Gentile F; Tosi B; Rossi A; Belardinelli L; Tesi C; Palandri C; Matucci R; Cerbai E; Olivotto I; Poggesi C; Mugelli A; Coppini R Br J Pharmacol; 2018 Jul; 175(13):2635-2652. PubMed ID: 29579779 [TBL] [Abstract][Full Text] [Related]
9. Novel Pharmacotherapy for Hypertrophic Cardiomyopathy. Wong TC; Martinez M Cardiol Clin; 2019 Feb; 37(1):113-117. PubMed ID: 30447712 [TBL] [Abstract][Full Text] [Related]
10. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy]. Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066 [TBL] [Abstract][Full Text] [Related]
11. Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond. Gaballa A; Jadam S; Desai MY Expert Opin Pharmacother; 2024 May; 25(7):915-924. PubMed ID: 38813944 [TBL] [Abstract][Full Text] [Related]
12. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents. Hajj Ali A; Mehra N; Desai MY Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068 [TBL] [Abstract][Full Text] [Related]
13. Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide. Willeford A; Silva Enciso J Pharmacotherapy; 2023 Dec; 43(12):1397-1404. PubMed ID: 37688422 [TBL] [Abstract][Full Text] [Related]
14. [Drug therapy of hypertrophic cardiomyopathy]. Hartmann A; Kaltenbach M; Hopf R Fortschr Med; 1992 Sep; 110(27):485-8. PubMed ID: 1358773 [TBL] [Abstract][Full Text] [Related]
15. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]
16. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Verlinden NJ; Coons JC Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556 [TBL] [Abstract][Full Text] [Related]
17. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Tamargo J; Tamargo M; Caballero R Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808 [TBL] [Abstract][Full Text] [Related]
18. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258 [TBL] [Abstract][Full Text] [Related]
19. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641 [TBL] [Abstract][Full Text] [Related]
20. Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. Olivotto I; Hellawell JL; Farzaneh-Far R; Blair C; Coppini R; Myers J; Belardinelli L; Maron MS Circ Heart Fail; 2016 Mar; 9(3):e002764. PubMed ID: 26915375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]